1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Research to Advance HBV Cure: HIV/HBV Co-Infection and HBV Mono-Infection (R01 Clinical Trial Not Allowed) is sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Invites applications for innovative basic, translational, and clinical research to identify and address challenges to achieving hepatitis B virus (HBV) cure in the presence or absence of human immunodeficiency virus (HIV).
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NOT-AI-20-014: Notice of Early Expiration of PAS-19-097 "Research to Advance HBV Cure: HIV/HBV Co-Infection and HBV Mono-infection (R01 Clinical Trial Not Allowed)" Notice of Early Expiration of PAS-19-097 "Research to Advance HBV Cure: HIV/HBV Co-Infection and HBV Mono-infection (R01 Clinical Trial Not Allowed)" Release Date: December 3, 2019 National Institute of Allergy and Infectious Diseases ( NIAID ) The purpose of this Notice is to inform the extramural community of the early expiration of PAS-19-097 , Research to Advance HBV Cure: HIV/HBV Co-Infection and HBV Mono-Infection (R01 Clinical Trial Not Allowed) effective January 8, 2020 .
Applications will no longer be accepted in response to this FOA after the January 7, 2020 AIDS Due Date. The Key Dates section of the FOA has been modified to change the Expiration Date from January 8, 2022 to January 8, 2020.
Please direct all inquiries to: Chris Lambros, PhD (HIV/HBV co-infection) National Institute of Allergy and Infectious Diseases (NIAID) Rajen Koshy, PhD (HBV mono-infection) Division of Microbiology and Infectious Diseases (DMID) National Institute of Allergy and Infectious Diseases (NIAID) Weekly TOC for this Announcement NIH... Turning Discovery Into Health ®
According to the current listing, eligibility includes: Check eligibility requirements in the official funding opportunity announcement. Most NIH grants can involve or be from non-US sources. Confirm the full requirements in the official notice before applying.
Research to Advance HBV Cure: HIV/HBV Co-Infection and HBV Mono-Infection (R01 Clinical Trial Not Allowed) is funded by National Institute of Allergy and Infectious Diseases (NIAID). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articleThe ReVAMPP network funds vaccine and monoclonal antibody research across five virus families. Here is who won, what the prototype-pathogen strategy means, and how to position for the next round.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read article